Based on the aggregated intelligence of 140,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech giant Gilead Sciences (Nasdaq: GILD) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Gilead's business and see what CAPS investors are saying about the stock right now.
Gilead facts
|
Headquarters (Founded)
|
Foster City, Calif. (1987)
|
|
Market Cap
|
$41.6 billion
|
|
Industry
|
Biotechnology
|
|
Trailing-12-Month Revenue
|
$6.4 billion
|
|
Management
|
Dr. John Martin (since 1996)
COO Dr. John Milligan (since 2007)
|
|
Return on Capital (Average, Past 3 Years)
|
30.6%
|
|
Cash / Debt
|
$3.3 billion / $1.3 billion
|
|
Competitors
|
GlaxoSmithKline (NYSE: GSK)
Abbott Labs (NYSE: ABT)
|
|
CAPS Members Bullish on GILD Also Bullish on
|
Johnson & Johnson (NYSE: JNJ)
General Electric (NYSE: GE)
|
|
CAPS Members Bearish on GILD Also Bearish on
|
Citigroup (NYSE: C)
Amazon (Nasdaq: AMZN)
|
Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.
On CAPS, 97.1% of the 1,752 members who have rated Gilead believe the stock will outperform the S&P 500 going forward. These bulls include mitleg and BGview.
Late last month, mitleg highlighted Gilead as a flu-fueled stock just waiting for liftoff:
This stock has languished while other sectors have driven the market. It is relatively inexpensive at the moment. Low peg, favorable pe, strong growth, low debt, and strong free cash flow. Given the connection to Tamiflu, I think as swine flu continues to terrorize here in the midwest and elsewhere, it could have a real strong quarter or two.
In an earlier pitch, BGview explains why Gilead should keep its lead in HIV:
As long as [Gilead's] Atripla continues to be the lead choice of a single dose / single pill HIV treatment, it will gain market share as doctors put patients on this drug. Recent study showing that the company's anti-HIV drugs can be used in Africa without constant lab test monitoring of patients should boost significantly its opportunities in developing markets. Negatives can be competitors coming up with their own one pill / once-per-day HIV drugs or alternative therapies appearing.
What do you think about Gilead, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. The CAPS community is waiting to hear your opinions. CAPS is 100% free, so get started!
Like this article? Get our best articles delivered direct to your inbox at no cost. Sign up for Foolwatch Weekly by entering your email below.
Terms & Conditions
RSS Headlines
Fool UK